Please assess the completion status of the following clinical trial:

Trial Title: Canadian Hemophilia Prophylaxis Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe hemophilia A (factor level less than 2%).~* Age greater than 1 year and less than or equal to 2.5 years.~* Normal joints using the World Federation of Hemophilia orthopedic scale.~* Normal radiographs of joints in which bleeding has occurred using the World Federation of Hemophilia radiographic scale.~* Platelet count of \> 150,000.~* Informed consent to participate.~Exclusion Criteria:~* Three or more clinically determined bleeds into any single elbow, knee or ankle.~* Presence or past history of a circulating inhibitor (level ≥ 0.5 Bethesda Units).~* Family judged to be non-compliant by the local hemophilia clinic director.~* Competing risk (symptomatic HIV infection, juvenile rheumatoid arthritis, metabolic bone disease, or other diseases known to cause or mimic arthritis.)

- Gender: MALE
- Minimum Age: 12 Months
- Maximum Age: 30 Months
- Healthy Volunteers: f

Study Arms:
- Factor VIII (Type: EXPERIMENTAL): escalating dose Factor VIII

Based on this trial design, predict the completion outcome and termination type (if applicable).